The 17F9 monoclonal antibody specifically binds to the 170-180 kDa transmembrane glycoprotein (P-glycoprotein), a product of the multidrug resistance-1 (MDR1) gene. This glycoprotein is expressed on MDR positive cells and has been reported to be expressed on many normal tissues, such as adrenal glands and endothelium, in the brain and skin. P-glycoprotein is known to impart drug resistance to cells by pumping many anti-cancer drugs out of the cytoplasm. 17F9 antibody is able to partially block the binding of UIC2 antibody (another MDR-specific monoclonal antibody).
The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.